Cargando…

Association between immune-related adverse event timing and treatment outcomes

The timing of immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI) is highly variable. Although the development of irAE has been associated with ICI clinical benefit, how irAE timing influences this association is unknown. We analyzed two independent cohorts includ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsiehchen, David, Naqash, Abdul Rafeh, Espinoza, Magdalena, Von Itzstein, Mitchell S., Cortellini, Alessio, Ricciuti, Biagio, Owen, Dwight H., Laharwal, Mehak, Toi, Yukihiro, Burke, Michael, Xie, Yang, Gerber, David E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741287/ https://www.ncbi.nlm.nih.gov/pubmed/35003896 http://dx.doi.org/10.1080/2162402X.2021.2017162

Ejemplares similares

T-cell tolerant fraction as a predictor of immune-related adverse events
por: Ostmeyer, Jared, et al.
Publicado: (2023)

Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?
por: von Itzstein, Mitchell S., et al.
Publicado: (2020)

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
por: Naqash, Abdul Rafeh, et al.
Publicado: (2019)

Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors
por: Hsiehchen, David, et al.
Publicado: (2019)

The Cooperative Landscape of Multinational Clinical Trials
por: Hsiehchen, David, et al.
Publicado: (2015)

Multinational teams and diseconomies of scale in collaborative research
por: Hsiehchen, David, et al.
Publicado: (2015)

Prevalence of Female Authors in Case Reports Published in the Medical Literature
por: Hsiehchen, David, et al.
Publicado: (2019)

Deficiencies in the Designs and Interventions of COVID-19 Clinical Trials
por: Hsiehchen, David, et al.
Publicado: (2020)

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report
por: Gonugunta, Amrit S., et al.
Publicado: (2022)

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
por: Ricciuti, Biagio, et al.
Publicado: (2020)

A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy
por: Fujiwara, Yu, et al.
Publicado: (2020)

The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC
por: Cortellini, Alessio
Publicado: (2020)

SAT-LB082 Neurosarcoidosis Presenting as Panhypopituitarism, Diabetes Insipidus and Sellar Mass
por: Saini, Khushpreet Kaur, et al.
Publicado: (2019)

Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients?
por: von Itzstein, Mitchell S., et al.
Publicado: (2020)

Circulating mitochondrial DNA as a biomarker for lung cancer screening
por: von Itzstein, Mitchell S., et al.
Publicado: (2022)

Representation of Investigators by Gender Among Authors of Phase 3 Oncology Trials Worldwide
por: Muquith, Maishara, et al.
Publicado: (2022)

Humoral and cellular correlates of a novel immune-related adverse event and its treatment
por: Gonugunta, Amrit S, et al.
Publicado: (2021)

Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report
por: Gerber, David E., et al.
Publicado: (2022)

Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series
por: Naqash, Abdul Rafeh, et al.
Publicado: (2019)

Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma
por: Lim, Mir, et al.
Publicado: (2023)

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
por: Macherla, Shravanti, et al.
Publicado: (2018)

Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups
por: Hsiehchen, David, et al.
Publicado: (2021)

Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
por: Isawa, Tsuyoshi, et al.
Publicado: (2022)

A Rare Case of Squamous Cell Carcinoma of the Esophagus in a Patient With Goltz Syndrome
por: Hafiz, Maida, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology
por: Choucair, Khalil, et al.
Publicado: (2022)

Distinct NSCLC EGFR Variants in a Family With Li-Fraumeni Syndrome: Case Report
por: Edmondson, Shelby, et al.
Publicado: (2022)

The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer
por: Naqash, Abdul Rafeh, et al.
Publicado: (2021)

INCIDENCE AND OUTCOME OF THROMBOTIC COMPLICATIONS IN PATIENTS WITH COVID-19 (SARS-COV-2) INFECTION: A SINGLE CENTER STUDY
por: SAHA, ADITI, et al.
Publicado: (2021)

Political partisanship and mobility restriction during the COVID-19 pandemic
por: Hsiehchen, D., et al.
Publicado: (2020)

Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors
por: Ahmed, Murtaza, et al.
Publicado: (2021)

Closing the gap: Contribution of surgical best practices to outcome differences between high‐ and low‐volume centers for lung cancer resection
por: von Itzstein, Mitchell S., et al.
Publicado: (2020)

The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma
por: Muhammed, Ambreen, et al.
Publicado: (2021)

Generalizability of machine learning methods in detecting adverse drug events from clinical narratives in electronic medical records
por: Zitu, Md Muntasir, et al.
Publicado: (2023)

Reply to Cortellini A
por: Ricciuti, Biagio, et al.
Publicado: (2020)

How lung cancer cells change identity
por: von Itzstein, Mitchell S, et al.
Publicado: (2021)

Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival
por: Choucair, Khalil, et al.
Publicado: (2023)

Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy
por: von Itzstein, Mitchell S., et al.
Publicado: (2022)

Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With None–Small-cell Lung Cancer
por: Owen, Dwight H., et al.
Publicado: (2018)

Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review
por: Marie, Mona A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_27at59uu4h322t40k9anlhld1e